Redhill Biopharma (RDHL) Receives Daily Media Sentiment Score of 0.06

Media stories about Redhill Biopharma (NASDAQ:RDHL) have trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Redhill Biopharma earned a news sentiment score of 0.06 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 46.7425873366162 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

These are some of the news stories that may have impacted Accern Sentiment’s analysis:

Shares of Redhill Biopharma (RDHL) opened at $5.15 on Tuesday. Redhill Biopharma has a 1-year low of $5.09 and a 1-year high of $12.09.

Several brokerages recently issued reports on RDHL. Roth Capital reaffirmed a “buy” rating and set a $27.00 price target on shares of Redhill Biopharma in a report on Wednesday, October 4th. Zacks Investment Research raised shares of Redhill Biopharma from a “sell” rating to a “hold” rating in a report on Wednesday, September 20th. HC Wainwright reissued a “buy” rating and set a $36.00 target price (up from $33.00) on shares of Redhill Biopharma in a report on Wednesday, October 4th. Seaport Global Securities began coverage on shares of Redhill Biopharma in a report on Friday, October 6th. They set a “buy” rating and a $19.00 target price on the stock. Finally, UBS AG began coverage on shares of Redhill Biopharma in a report on Wednesday, September 13th. They set a “reduce” rating on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. Redhill Biopharma currently has an average rating of “Buy” and an average price target of $23.35.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Markets Daily and is the property of of Markets Daily. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be read at

Redhill Biopharma Company Profile

Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.

Insider Buying and Selling by Quarter for Redhill Biopharma (NASDAQ:RDHL)

Receive News & Ratings for Redhill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma Ltd. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply